厄贝沙坦杂质19 | 133690-91-2

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 厄贝沙坦杂质19
• 英文名称: 2-cyano-4'-(azidomethyl)biphenyl
• 英文别名: 4'-(azidomethyl)-2-biphenylcarbonitrile；4'-(azidomethyl)[1,1'-biphenyl]-2-carbonitrile；4-azidomethyl-2'-cyanobiphenyl；2-[4-(azidomethyl)phenyl]benzonitrile
• CAS: 133690-91-2
• 化学式: C₁₄H₁₀N₄
• 分子量: 234.26
• InChiKey: LANSUNWWSUCCJT-UHFFFAOYSA-N

物化性质

• 熔点：
  61 - 70°C
• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  38.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  厄贝沙坦杂质19 在 palladium on activated charcoal 吡啶 、 trimethyltin azide 、 potassium tert-butylate 、 氢气 、 sodium methylate 、 溶剂黄146 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 、 氯仿 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 25.0 ℃ 、275.79 kPa 条件下， 反应 212.0h， 生成 5-butyl-2,4-dihydro-2-pentyl-4-<<2'-(1H-tetrazol-5-yl)<1,1'-biphenyl>-4-yl>methyl>-3H-1,2,4-triazol-3-one
  参考文献：
  名称：

  Synthesis and structure-activity relationships of nonpeptide, potent triazolone-based angiotensin II receptor antagonists

  摘要：

  2,5-Dibutyl-2,4-dihydro-4-[[2-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4'-yl]methyl] -3H-1,2,4-triazol-3-one, SC-51316, was synthesized as a potent and orally active angiotensin II (AII) receptor antagonist with a long duration of action. To explore the lipophilic pocket in the AII receptor interacting with the substituent at the 2-position of triazolone-based antagonists, a series of compounds were prepared and evaluated for receptor binding affinity and antagonism of AII-contracted rabbit aortic rings. It has been found that the pocket is very spacious and can accommodate different sizes of lipophilic groups and various functionalities. Acidic groups generally result in a slight decrease in binding affinity. Branched chains are unfavorable. The freedom of rotation around C2-C3 in the flexible side chain is crucial for good binding. The 2-phenylethyl-substituted triazolone analogue exhibits the highest in vitro potency among all compounds that have been synthesized.

  DOI：

  10.1021/jm00067a015
• 作为产物：
  描述：

  2-氰基-4'-甲基联苯 在 N-溴代丁二酰亚胺(NBS) 、 sodium azide 、 偶氮二异丁腈 作用下， 以 四氯化碳 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 厄贝沙坦杂质19
  参考文献：
  名称：

  Synthesis and structure-activity relationships of nonpeptide, potent triazolone-based angiotensin II receptor antagonists

  摘要：

  2,5-Dibutyl-2,4-dihydro-4-[[2-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4'-yl]methyl] -3H-1,2,4-triazol-3-one, SC-51316, was synthesized as a potent and orally active angiotensin II (AII) receptor antagonist with a long duration of action. To explore the lipophilic pocket in the AII receptor interacting with the substituent at the 2-position of triazolone-based antagonists, a series of compounds were prepared and evaluated for receptor binding affinity and antagonism of AII-contracted rabbit aortic rings. It has been found that the pocket is very spacious and can accommodate different sizes of lipophilic groups and various functionalities. Acidic groups generally result in a slight decrease in binding affinity. Branched chains are unfavorable. The freedom of rotation around C2-C3 in the flexible side chain is crucial for good binding. The 2-phenylethyl-substituted triazolone analogue exhibits the highest in vitro potency among all compounds that have been synthesized.

  DOI：

  10.1021/jm00067a015

文献信息

• Design, synthesis and pharmacological analysis of 5-[4′-(substituted-methyl)[1,1′-biphenyl]-2-yl]-1H-tetrazoles
  作者：Atulkumar Kamble、Ravindra Kamble、Suneel Dodamani、Sunil Jalalpure、Vijaykumar Rasal、Mahadev Kumbar、Shrinivas Joshi、Sheshagiri Dixit

  DOI：10.1007/s12272-017-0887-0

  日期：2017.4

  In the present paper 5-[4′-(4-[(4-aryloxy)methyl]-1H-1,2,3-triazol-1-yl}methyl)[1,1′-biphenyl]-2-yl]-1H-tetrazoles (5a–g) and [2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl-substituted-1-carbodithioates (11h–q) have been designed and synthesized. These compounds were subjected to docking (against AT1 receptor protein enzyme in complex with Lisinopril), in vitro angiotensin converting enzyme inhibition

  在本文中 5-[4'-(4-[(4-芳氧基)甲基]-1H-1,2,3-三唑-1-基}甲基)[1,1'-联苯]-2-基]-1H-四唑 (5a-g) 和 [2'-(1H-四唑-5-基)[1,1'-联苯]-4-基]甲基-取代的-1-碳二硫代酸酯 (11h-q)已经设计和合成。这些化合物经过对接（针对与赖诺普利复合的 AT1 受体蛋白酶）、体外血管紧张素转化酶抑制、抗增殖、抗炎筛选（通过卵白蛋白变性抑制和红细胞膜稳定试验），最后抗- 真菌活性分析。一些化合物已显示出显着的药理特性。
• Substituted triazolinones, triazolinethiones, and triazolinimines as
  申请人：Merck & Co., Inc.

  公开号：US05411980A1

  公开（公告）日：1995-05-02

  There are disclosed new substituted triazolinone, triazolinethione, and triazolinimine compounds which are useful as angiotensin II antagonists. These compounds have the general formula: ##STR1## wherein G is R.sup.1 or ##STR2##

  已披露了新的取代三唑酮，三唑硫酮和三唑亚胺化合物，这些化合物可用作血管紧张素II拮抗剂。这些化合物具有一般式：##STR1## 其中G为R.sup.1或##STR2##
• Substituted triazoles as angiotensin II antagonists
  申请人：Merck & Co., Inc.

  公开号：US05336778A1

  公开（公告）日：1994-08-09

  Novel substituted triazoles of the formula (I), which are useful as angiotensin II antagonists, are disclosed. ##STR1##

  本发明揭示了作为肾素-血管紧张素系统 II 受体拮抗剂有用的化合物(I)的新型取代三唑。
• Synthesis of non‐toxic anticancer active forskolin‐indole‐triazole conjugates along with their in silico succinate dehydrogenase inhibition studies
  作者：Devendar Ponnam、Niranjana Kumar Arigari、Satya Srinivas Kalvagunta Venkata Naga、Kotesh Kumar Jonnala、Shilpi Singh、Abha Meena、Pallavi Misra、Suaib Luqman

  DOI：10.1002/jhet.4332

  日期：2021.11

  important three different pharmacophores, forskolin, indole and 1,2,3-triazoles are coupled to obtain a hybrid molecule. Here, we described the synthesis of novel series of forskolin-indole-triazole conjugates 5a-5l by using the Cu(I) catalyzed 1,3-dipolar cycloaddition reaction. Furthermore, the biological significance of the synthesized molecules was assessed by in silico and in vitro modes. All the synthesized

  生物学上重要的三种不同的药效团，毛喉素、吲哚和 1,2,3-三唑偶联以获得混合分子。在这里，我们描述了使用 Cu(I) 催化的 1,3-偶极环加成反应合成新系列的毛喉素-吲哚-三唑共轭物 5a-5l。此外，合成分子的生物学意义通过计算机模拟和体外模式进行评估。评估了所有合成化合物对 PC-3、MCF-7、MDA-MB-231、COLO-205、HeLa、WRL-68、RAJI、CHANG 和 RAW-264.7 细胞系的体外抗癌活性。发现化合物 5g 在所有测试的细胞系中最有效（IC 50范围为 9.6–21.66 μg/ml，COLO-205 除外），观察到 5a、5b 和 5k 仅对 WRL-68 发挥作用（IC 50范围 27.69–48.18 μg/ml），与亲本 3（IC 50  > 100 μg/ml，测试浓度 10–50 μg/ml）和标准多柔比星（IC 50范围 0.42–3
• Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles
  作者：Wallace T. Ashton、Christine L. Cantone、Linda L. Chang、Steven M. Hutchins、Robert A. Strelitz、Malcolm MacCoss、Raymond S. L. Chang、Victor J. Lotti、Kristie A. Faust

  DOI：10.1021/jm00057a009

  日期：1993.3

  By a variety of synthetic routes, we have synthesized a series of 3,4,5-trisubstituted 4H-1,2,4-triazoles and a related series of 3H-imidazo[1,2-b][1,2,4]triazoles and evaluated them in vitro and in vivo as angiotensin II (AII) antagonists. Principal efforts focused on triazoles bearing an n-alkyl substitutent at C3 and a 4-[(2-carboxybenzoyl)amino]benzyl, (2'-carboxybiphenyl-4-yl)methyl, or [2'-(

  通过多种合成途径，我们合成了一系列3,4,5-三取代的4H-1,2,4-三唑和相关的系列3H-咪唑并[1,2-b] [1,2,4三唑类药物，并在体外和体内将其评估为血管紧张素II（AII）拮抗剂。主要工作集中在三唑在C3处带有正烷基取代基和4-[（2-羧基苯甲酰基）氨基]苄基，（2'-羧基联苯-4-基）甲基或[2'-（1H-四唑-5）在N 4处的-基）联苯基-4-基]甲基侧链。在C5的众多变化中，苄硫基的效力最佳。特别值得注意的是3-正丁基-5-[（2-羧基苄基）硫基] -4-[[2'-（1H-四唑-5-基）联苯-4-基]甲基] -4H-1,2 ，4-三唑（71，IC50 1.4 nM），以0.3 mg / kg iv的速度阻断了清醒大鼠的AII升压反应，作用时间约为6小时，类似于DuP 753。尽管71的口服活性仅高10倍，但单酸类似物62具有良好的口服生物利用度。在双环衍生物中，最有效的是2-n-丁基5